Session

IBD: Mixed trials

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY
EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION
DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE
INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS
SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

IBD: Mixed trials  et al.

SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS
SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS

IBD: Mixed trials  et al.

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE
INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

IBD: Mixed trials  et al.

DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION
DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION

IBD: Mixed trials  et al.

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY
EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

IBD: Mixed trials  et al.

Item 1 - 10 / 10
1